Spotlight On... Luminex bumps up offer for Nanosphere to $77M; WHO expands use for nonsurgical circumcision device; Nucleix gets $3M to back bladder cancer urine test; and more...

Luminex ($LMNX) had offered to buy molecular microbiology and diagnostic company Nanosphere ($NSPH) for $58 million. But it was forced to raise its offer to about $77 million after an unsolicited third party offered $1.50 per share for the company. The original offer was for $1.35 and the current agreed-upon offer is for $1.70 per share. More

> The World Health Organization (WHO) has expanded its prior prequalification for the PrePex male nonsurgical circumcision device to adolescents who are 13 years are older; the agency previously prequalified it for adult males. More

> Yissum Research Development Company of the Hebrew University of Jerusalem has received $1.2 million from Aurum Ventures to develop a diagnostic test for multiple diseases by analyzing circulating DNA released from dying cells. More

> Israeli epigenetic biomarker company Nucleix has raised $3 million to back its urine test for bladder cancer and to develop liquid biopsy tests for other cancers. The urine test is expected to receive a CE mark and start marketing in Europe next quarter. More